Becker's Healthcare June 14, 2024
Anecdotally, some people taking GLP-1s report having less cravings for more than just food.
Several clinical trials are underway to examine whether semaglutide, the active ingredient in Ozempic and Wegovy, can reduce the desire for alcohol. Evidence has indicated the drugs can reduce pleasure associated with drinking alcohol, but it is still uncertain whether they are safe and effective for treating alcohol use disorder. Trials investigating GLP-1s as potential treatments for drug addiction and for diminishing the risk of dementia are also underway.
At AHIP’s June 2024 conference in Las Vegas, three physician executives weighed in on whether GLP-1s have the potential to curb other kinds of addictions:
Melanie Jay, MD, Director, NYU Langone Comprehensive Program on Obesity Research:
We don’t...
Today's Sponsors
Today's Sponsor